Reproxalap Ophthalmic Solution (0.25%)
ADX-102-DED-009
Phase 2 small_molecule completed
Quick answer
Reproxalap Ophthalmic Solution (0.25%) for Dry Eye Syndrome is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Dry Eye Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed